Wedbush raised the firm’s price target on Zentalis to $15 from $12 and keeps a Neutral rating on the shares. The firm notes the company reported Q4/FY23 results, and confirmed development timelines for WEE1 inhibitor azenosertib. The company remains on track to share multiple azeno datasets in 2024 and 2025, with the goal of submitting an NDA in a gynecologic malignancy, Wedbush adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ZNTL:
- Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
- Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates
- Zentalis sees cash runway into 2026
- Zentalis announces anticipated upcoming milestones
- Zentalis reports 2023 EPS ($4.47), consensus ($4.54)
